recombinant mouse vegf c  (Cusabio)

Journal: Communications Biology

Article Title: Preventing periprosthetic osteolysis in aging populations through lymphatic activation and stem cell-associated secretory phenotype inhibition

doi: 10.1038/s42003-024-06664-x

Figure Lengend Snippet: a Micro-CT images illustrating cranial bone resorption from both superior and inferior perspectives after continuous TAP treatment for 7 or 14 days, concomitant with subcutaneous injection of recombinant VEGF-C. b TRAP staining in mouse cranial bones following TAP implantation, combined with recombinant VEGF-C injection. Scale bars: 100 μm. c H&E staining in mouse cranial bones following TAP implantation, combined with recombinant VEGF-C injection. Scale bars: 100 μm. d IF staining for DAPI with LYVE1 (green) and PROX1 (red). Scale bars, 100 μm. e Quantification of the lytic area in calvarial bone tissues analyzed by micro-CT ( n = 6). f Quantification of TRAP-stained areas in calvarial bone sections ( n = 6). g Quantification of inflammatory infiltrating cells in calvarial bone sections ( n = 6). h , i The corresponding quantitative data for LYVE1 (green) and PROX1 (red) expressions in cranial bones on day 7 or day 14 after combined TAP and recombinant VEGF-C treatments ( n = 6). Data are shown as means ± SD. Significance was assessed through one-way ANOVA.

Article Snippet: For pharmacological activation of lymphatic vessels in mouse bone tissue, recombinant VEGF-C protein (SinoBiological) at a concentration of 10 μg/mL was subcutaneously injected onto the surface of the skull.

Techniques: Micro-CT, Injection, Recombinant, Staining

Journal: Communications Biology

Article Title: Preventing periprosthetic osteolysis in aging populations through lymphatic activation and stem cell-associated secretory phenotype inhibition

doi: 10.1038/s42003-024-06664-x

Figure Lengend Snippet: a Micro-CT images depict cranial bone resorption from both superior and inferior perspectives after continuous LPS treatment for 14 days, concomitant with subcutaneous injection of recombinant VEGF-C. b TRAP staining in mouse cranial bones following LPS treatment, combined with recombinant VEGF-C injection. Scale bars: 100 μm. c H&E staining in mouse cranial bones following LPS treatment, combined with recombinant VEGF-C injection. Scale bars: 100 μm. d IF staining for DAPI with LYVE1 (green) and PROX1 (red). Scale bars, 100 μm. e Quantification of the lytic area in calvarial bone tissues analyzed by micro-CT ( n = 6). f Quantification of TRAP-stained areas in calvarial bone sections ( n = 6). g Quantification of inflammatory infiltrating cells in calvarial bone sections ( n = 6). h , i The corresponding quantitative data for LYVE1 (green) and PROX1 (red) expressions in cranial bones on day 14 after combined LPS and recombinant VEGF-C treatments ( n = 6). j Micro-CT images depict cranial bone resorption from both superior and inferior perspectives after continuous TNF-α treatment for 14 days, concomitant with subcutaneous injection of recombinant VEGF-C. k TRAP staining in mouse cranial bones following TNF-α treatment, combined with recombinant VEGF-C injection. Scale bars: 100 μm. l H&E staining in mouse cranial bones following TNF-α treatment, combined with recombinant VEGF-C injection. Scale bars: 100 μm. m IF staining for DAPI with LYVE1 (green) and PROX1 (red). Scale bars, 100 μm. n Quantification of the lytic area in calvarial bone tissues analyzed by micro-CT ( n = 6). o Quantification of TRAP-stained areas in calvarial bone sections ( n = 6). p Quantification of inflammatory infiltrating cells in calvarial bone sections ( n = 6). q , r The corresponding quantitative data for LYVE1 (green) and PROX1 (red) expressions in cranial bones on day 14 after combined TNF-α and recombinant VEGF-C treatments ( n = 6). Data are shown as means ± SD. Significance was assessed through one-way ANOVA.

Article Snippet: For pharmacological activation of lymphatic vessels in mouse bone tissue, recombinant VEGF-C protein (SinoBiological) at a concentration of 10 μg/mL was subcutaneously injected onto the surface of the skull.

Techniques: Micro-CT, Injection, Recombinant, Staining

Journal: Communications Biology

Article Title: Preventing periprosthetic osteolysis in aging populations through lymphatic activation and stem cell-associated secretory phenotype inhibition

doi: 10.1038/s42003-024-06664-x

Figure Lengend Snippet: a Micro-CT images illustrating cranial bone resorption in aging mice from both superior and inferior perspectives after continuous TAP treatment for 14 days, concomitant with subcutaneous injection of recombinant VEGF-C. b Quantification of the lytic area in calvarial bone tissues analyzed by micro-CT ( n = 6). c TRAP staining in aging mouse cranial bones after TAP implantation. Scale bars: 100 μm. d H&E staining in aging mouse cranial bones after TAP implantation. Scale bars: 100 μm. e IF staining for DAPI with LYVE1 (green) and PROX1 (red). Scale bars, 100 μm. f Quantification of TRAP-stained areas in calvarial bone sections ( n = 6). g Quantification of inflammatory infiltrating cells in calvarial bone sections ( n = 6). h , i The corresponding quantitative data for LYVE1 (green) and PROX1 (red) expressions in the cranial bones of aging mice on day 14 after combined TAP and recombinant VEGF-C treatments ( n = 6). j – l Representative immunofluorescence images and the corresponding quantification data for LYVE1 (green) and PROX1 (red) expressions in the cranial bones of mice at different ages ( n = 6). m – p Representative immunofluorescence images and the corresponding quantification data for p53, γH2AX and Perilipin expressions in the cranial bones of mice at different ages ( n = 6). Data are shown as means ± SD. Significance was assessed through one-way ANOVA.

Article Snippet: For pharmacological activation of lymphatic vessels in mouse bone tissue, recombinant VEGF-C protein (SinoBiological) at a concentration of 10 μg/mL was subcutaneously injected onto the surface of the skull.

Techniques: Micro-CT, Injection, Recombinant, Staining, Immunofluorescence

Journal: Communications Biology

Article Title: Preventing periprosthetic osteolysis in aging populations through lymphatic activation and stem cell-associated secretory phenotype inhibition

doi: 10.1038/s42003-024-06664-x

Figure Lengend Snippet: a Model of co-culture involving BMSCs treated with adipogenic differentiation medium and LECs. Mouse bone marrow-derived stem cells were seeded in the upper insert at a density of 5 × 10 4 cells/well, while the lower layer of LECs was evenly plated at a density of 1 × 10 5 cells/well. b IF images of Anti-LYVE1 antibody and Anti-PROX1 antibody demonstrate that upper-layer adipogenically differentiated BMSCs inhibit the proliferation of lower-layer LECs. However, this inhibitory effect can be reversed by using JAK inhibitor on the upper insert. Scale bar, 50 µm. c Micro-CT images illustrate cranial bone resorption from both superior and inferior perspectives after continuous TAP treatment for 14 days, along with subcutaneous injection of recombinant VEGF-C, oral administration of JAK inhibitor, or their combination. d TRAP staining was performed on mouse cranial bones following TAP treatment, combined with subcutaneous injection of recombinant VEGF-C, oral administration of JAK inhibitor, or their combination. Scale bars: 100 μm. e H&E staining was performed on mouse cranial bones following TAP treatment, combined with subcutaneous injection of recombinant VEGF-C, oral administration of JAK inhibitor, or their combination. Scale bars: 100 μm. f IF staining for DAPI with LYVE1 (green) and PROX1 (red). Scale bars, 100 μm. g Micro-CT images illustrating cranial bone resorption in aging mice from both superior and inferior perspectives following TAP treatment, combined with subcutaneous injection of recombinant VEGF-C, oral administration of JAK inhibitor, or their combination. h Quantification of TRAP-stained areas in calvarial bone sections ( n = 6). i Quantification of inflammatory infiltrating cells in calvarial bone sections ( n = 6). j , k The corresponding quantitative data for LYVE1 (green) and PROX1 (red) expressions in cranial bones on day 14 after combined TAP treatment, subcutaneous injection of recombinant VEGF-C, oral administration of JAK inhibitor, or their combination ( n = 6). Data are shown as means ± SD. Significance was assessed through one-way ANOVA.

Article Snippet: For pharmacological activation of lymphatic vessels in mouse bone tissue, recombinant VEGF-C protein (SinoBiological) at a concentration of 10 μg/mL was subcutaneously injected onto the surface of the skull.

Techniques: Co-Culture Assay, Derivative Assay, Micro-CT, Injection, Recombinant, Staining